This study investigates improved factor combinations for the in vivo reprogramming of activated cardiac myofibroblasts into cardiomyocyte-like cells to promote heart regeneration.
onrenewable cell types such as cardiomyocytes die with injury and aging, causing irreversible damage to normal heart function.In vivo direct reprogramming can promote heart regeneration by converting proliferative, extracellular matrix-secreting activated cardiac myofibroblasts into cardiomyocytes.This approach replenishes cardiomyocytes while simultaneously ameliorating cardiac fibrosis.Previous studies have reported in vivo cardiac fibroblast reprogramming into cardiomyocytes through the expression of transcription factors (such as GATA4, MEF2C, TBX5 GMT), microRNA silencing, or transcription factor expression in conjunction with small molecule activators. 1 However, our previous study showed that activated myofibroblasts, the ideal targets of in vivo cardiac reprogramming, are more difficult to reprogram than resident cardiac fibroblasts in vitro. 2 The efficiency remains unclear of in vivo cardiac myofibroblast-to-cardiomyocyte-like cell reprogramming using stringent lineage tracing systems.Furthermore, the discovery of genetic and chemical boosters of in vitro myofibroblast-to-cardiomyocyte reprogramming 2 (Tao Y,
Wu et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: